Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid

Citation
H. Sambatakou et al., Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid, INT J ANT A, 18(5), 2001, pp. 441-444
Citations number
15
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Microbiology
Journal title
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
ISSN journal
0924-8579 → ACNP
Volume
18
Issue
5
Year of publication
2001
Pages
441 - 444
Database
ISI
SICI code
0924-8579(200111)18:5<441:POFIUC>2.0.ZU;2-O
Abstract
In order to study the penetration of routinely used fluoroquinolones in the ascitic fluid of patients with uncompensated cirrhosis the following doses were given. Three patients received three consecutive iv doses of 200 mg o f ciprofloxacin, six patients, three consecutive iv doses of 300 mg of cipr ofloxacin, seven others, three consecutive iv doses of 400 mg of pefloxacin and six, three consecutive iv doses of 400 mg of ofloxacin. Drug levels in serum and the ascitic fluid were monitored at regular time intervals. Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciproflo xacin, of pefloxacin and of ofloxacin in serum were 2.11, 2.45, 9.21 and 8. 86 mug/ml, respectively and in the ascitic fluid 0.67, 0.45. 6.09 and 5.83 mug/ml, respectively T-1/2 was 3.19 +/- 0.73, 3.55 +/- 1.68, 15.60 +/- 12.4 0 and 9.45 +/- 3.14 h, respectively with AUC of 3.62 +/- 4.02, 7.39 +/- 4.7 0, 137.85 +/- 63.96 and 119.8 +/- 16.83 mg/l h. Urinary excretion of ciprof loxacin and of ofloxacin was similar to healthy individuals but pefloxacin showed a mean urinary excretion of 30.11%. It is concluded that pefloxacin and ofloxacin at the administered iv doses result in serum and ascitic flui d levels above the MICs of the common pathogens causing spontaneous bacteri al peritonitis and that they should be administered to cirrhotic patients i n dosing regimens similar to those in patients with normal hepatic function . The use of ciprofloxacin requires further studies to define the appropria te dose. (C) 2001 Published by Elsevier Science B.V. and International Soci ety of Chemotherapy.